Moreover, there were no significant differences in survival times between dogs with AR+ and AR− PRAD tumors, and they featured an overall MST of 2 and 3.5 days, respectively (p > 0.05) (Figure S4). This evidence concerns the gene AR and prostate adenocarcinoma.